Application of polypeptide in preparation of anti-aging skin care product

Abstract

The invention belongs to the technical field of biological peptides, and particularly relates to an application of a polypeptide in preparation of an anti-aging skin care product. The invention provides application of polypeptide in preparation of an anti-aging skin care product. The amino acid sequence of the polypeptide is as follows: Ala-Glu-Pro-Val-Pro-Leu. The polypeptide provided by the invention can significantly reduce the length and depth of the forehead wrinkles of a subject; the area and depth of the Chinese character'chuan '-shaped patterns are obviously reduced; the number and depth of crow's feet are obviously reduced; the volume and the depth of nasolabial folds are obviously reduced, so that the polypeptide disclosed by the invention has an obvious anti-wrinkle effect. The polypeptide essence disclosed by the invention is mild and non-irritant, and a subject with sensitive skin does not have untoward effects related to the polypeptide disclosed by the invention.

Description

Technical Field

[0001] The present invention belongs to the technical field of bio - peptides, and specifically relates to the application of polypeptides in the preparation of anti - aging skin care products. Background Art

[0002] The skin is the largest and most important organ of the human body, which undergoes a complex and cumulative aging process throughout life. The increase in facial wrinkles is an important sign of aging. The clinical characteristics of skin aging are manifested as deep wrinkles, loss of skin elasticity, dryness, relaxation, roughness, etc. The aging of the skin is mainly caused by endogenous and exogenous factors. External aging is mainly caused by many factors such as environment, cellular oxidation, etc., such as solar radiation, cigarette smoke or other pollution factors, among which ultraviolet radiation is the main factor of photo - aging. Skin aging is a natural phenomenon in the process of life. Although it is unstoppable, the pace of aging can be slowed down by some means.

[0003] Currently, invasive methods are usually used to remove wrinkles. For example, injecting botulinum toxin (Botox) can paralyze and relax the facial expression muscles to achieve the effect of quickly removing wrinkles. Botox acts on the cholinergic motor nerve endings, that is, at the neuromuscular junction or synapse, inhibiting the release of the neurotransmitter acetylcholine from the presynaptic membrane, so that the muscle fibers cannot contract, the muscle tension is reduced, and thus the muscle is paralyzed. This muscle relaxation time is limited and is also accompanied by great risks, such as infection, pain, facial paralysis caused by improper injection, etc.

[0004] With the development of the economy and the improvement of living standards, people pay more and more attention to skin care. The market scale of anti - aging and anti - wrinkle products is huge, and more active substances are needed to be applied to skin repair and firming products to meet the needs of consumers. Summary of the Invention

[0005] The purpose of the present invention is to provide the application of polypeptides in the preparation of anti - aging skin care products; the amino acid sequence of the polypeptide is: Ala - Glu - Pro - Val - Pro - Leu.

[0006] Further, the anti - aging is to reduce facial wrinkles.

[0007] Further, the facial wrinkles are forehead wrinkles.

[0008] Further, the facial wrinkles are glabellar lines.

[0009] Further, the facial wrinkles are crow's feet.

[0010] Further, the facial wrinkles are nasolabial folds.

[0011] Further, the skin care products include lotions, aqueous solutions, essence, facial masks, creams, gels, sprays, gels, powder injections.

[0012] Furthermore, the amount of the polypeptide added to the skin care product is 0.001–1.0 wt%.

[0013] Furthermore, the formula of the essence is as follows: 0.01% to 1.0% of the polypeptide, 0.05% to 2.0% of sodium hyaluronate, 0.01% to 1.0% of hydrolyzed sodium hyaluronate, 1.0% to 5.0% of hexanediol, 1% to 5% of glycerin, 2% to 10% of 1,3-butanediol, 0.05% to 1.0% of carbomer, 0.1% to 0.5% of L-arginine, and the balance being deionized water.

[0014] Further, the formulation of the spray is as follows: 0.001% to 1.0% of the polypeptide, 0.05% to 2.0% of sodium hyaluronate, 0.01% to 1.0% of hydrolyzed sodium hyaluronate, 1.0% to 5.0% of hexanediol, and the balance being deionized water.

[0015] Further, the cream's formula is as follows: 0.05%–1.0% of the polypeptide, 0.05%–2.0% of sodium hyaluronate, 0.01%–1.0% of hydrolyzed sodium hyaluronate, 1.0%–5.0% of hexanediol, 3%–4% of cetearyl alcohol, 0.5%–2% of stearic acid, 0.5%–2% of cocoyl glucoside, 1%–3% of glyceryl stearate, 1%–3% of polydimethylsiloxane, 1%–3% of pentaerythritol tetra(ethylhexanoate), 1%–3% of caprylic / capric triglyceride, 1%–5% of glycerin, 2%–10% of 1,3-butanediol, 0.01%–0.08% of EDTA-2NA, 0.1%–0.8% of phenoxyethanol, 0.05%–2% of xanthan gum, with the balance being deionized water.

[0016] The beneficial effects of this invention are:

[0017] This invention provides the application of a polypeptide with the amino acid sequence Ala-Glu-Pro-Val-Pro-Leu in the preparation of anti-aging skincare products. Efficacy tests have demonstrated that the polypeptide of this invention can significantly reduce the length and depth of forehead wrinkles; significantly reduce the area and depth of frown lines; significantly reduce the number and depth of crow's feet; and significantly reduce the volume and depth of nasolabial folds, proving that the polypeptide of this invention has significant anti-wrinkle effects. The polypeptide essence of this invention is gentle and non-irritating; no adverse reactions related to the presence of the polypeptide of this invention were observed in subjects with sensitive skin, indicating broad application prospects. Attached Figure Description

[0018] Figure 1 This is a comparison chart of the length of forehead wrinkles before and after using the product in Example 5.

[0019] Figure 2 This is a comparison chart of forehead wrinkle depth before and after using the product in Example 5.

[0020] Figure 3 Comparison chart of the area of the glabellar lines before and after using the product in Example 5.

[0021] Figure 4 Comparison chart of the depth of the glabellar lines before and after using the product in Example 5.

[0022] Figure 5 Comparison chart of the number of crow's feet before and after using the product in Example 5.

[0023] Figure 6 Comparison chart of the depth of the crow's feet before and after using the product in Example 5.

[0024] Figure 7 Comparison chart of the volume of the nasolabial folds before and after using the product in Example 5.

[0025] Figure 8 Comparison chart of the depth of the nasolabial folds before and after using the product in Example 5.

[0026] Figure 9 Illustration showing an effective case of improving the nasolabial folds of Subject No. 29 in Example 5.

[0027] Figure 10 Illustration showing an effective case of improving the nasolabial folds of Subject No. 9 in Example 5.

[0028] Figure 11 Illustration showing an effective case of improving the nasolabial folds of Subject No. 28 in Example 5.

[0029] Figure 12 Illustration showing an effective case of improving the glabellar lines of Subject No. 7 in Example 5.

[0030] Figure 13 Illustration showing an effective case of improving the glabellar lines of Subject No. 11 in Example 5.

[0031] Figure 14 Illustration showing an effective case of improving the glabellar lines of Subject No. 28 in Example 5.

[0032] Figure 15 Illustration showing an effective case of improving the crow's feet of Subject No. 30 in Example 5.

[0033] Figure 16 Illustration showing an effective case of improving the crow's feet of Subject No. 33 in Example 5.

[0034] Figure 17 Illustration showing an effective case of improving the crow's feet of Subject No. 14 in Example 5.

[0035] Figure 18 Illustration showing an effective case of improving the forehead lines of Subject No. 19 in Example 5.

[0036] Figure 19This is a demonstration image of the effective improvement in forehead wrinkles in subject number 27 of Example 5.

[0037] Figure 20 This is a diagram illustrating the effective improvement in forehead wrinkles in subject number 26 of Example 5. Detailed Implementation

[0038] The present invention will be further described in detail below through specific embodiments.

[0039] Example 1: Preparation of the polypeptide of the present invention

[0040] The polypeptide powder of the present invention is prepared according to the patent method of application number 202110747197.5.

[0041] Example 2: Preparation of the polypeptide essence of the present invention

[0042] The preparation was carried out using the polypeptide powder obtained in Example 1.

[0043] The formula for the polypeptide essence is as follows: 0.1% polypeptide, 0.1% sodium hyaluronate, 0.05% hydrolyzed sodium hyaluronate, 1.5% hexanediol, 2% glycerin, 5% 1,3-butanediol, 0.35% carbomer, 0.35% L-arginine, and the balance is deionized water.

[0044] Preparation process of peptide essence: After high-temperature sterilization of deionized water, heat it to 85°C, add carbomer, place it in a constant temperature water bath and keep it warm for 3 hours. The temperature of the constant temperature water bath is controlled at about 80°C. Then stir and cool it to room temperature. Add L-arginine, stir evenly, and then add peptide, sodium hyaluronate, hydrolyzed sodium hyaluronate, hexanediol, glycerin, 1,3-butanediol and phenoxyethanol in sequence. Stir thoroughly until all materials are dissolved to obtain the essence.

[0045] Example 3: Preparation of the polypeptide spray of the present invention

[0046] The preparation was carried out using the polypeptide powder obtained in Example 1.

[0047] The formulation of the peptide spray is as follows: 0.1% peptide, 0.1% sodium hyaluronate, 0.1% hydrolyzed sodium hyaluronate, 1.5% hexanediol, and the balance is deionized water.

[0048] Preparation process of peptide spray: After sterilizing deionized water at high temperature, keep the temperature at room temperature, add sodium hyaluronate, hydrolyzed sodium hyaluronate, hexanediol and peptide in sequence, stir thoroughly until all materials are dissolved, fill and obtain the spray.

[0049] Example 4: Preparation of the polypeptide face cream of the present invention

[0050] The preparation was carried out using the polypeptide powder obtained in Example 1.

[0051] The formula for the peptide face cream is as follows: peptide 0.1%, sodium hyaluronate 0.1%, hydrolyzed sodium hyaluronate 0.05%, hexanediol 1.5%, cetearyl alcohol 3%, stearic acid 0.5%, cocoyl glucoside 2%, glyceryl stearate 2%, polydimethylsiloxane 3%, pentaerythritol tetra(ethylhexanoate) ester 3%, caprylic / capric triglyceride 5%, glycerin 1.5%, 1,3-butanediol 5%, EDTA-2NA 0.05%, phenoxyethanol 0.5%, xanthan gum 0.1%, and the balance being deionized water.

[0052] Preparation process of peptide face cream: After high-temperature sterilization of deionized water, heat it to 80°C in an emulsifying tank. Add the aqueous phase raw materials (sodium hyaluronate, hydrolyzed sodium hyaluronate, hexanediol, glycerin, 1,3-butanediol, EDTA-2NA, xanthan gum) sequentially and set aside. Add the oil phase raw materials (cetearearyl alcohol, stearic acid, cocoyl glucoside, glyceryl stearate, polydimethylsiloxane, pentaerythritol tetra(ethylhexanoate), caprylic / capric triglyceride) to the oil phase tank and heat to 80°C, stirring until all materials are dissolved. Transfer the material from the oil phase tank to the emulsifying tank and begin the emulsification process, homogenizing four times for 5 minutes each time. After emulsification, cool and stir to 45°C. Add the peptides and phenoxyethanol sequentially to the emulsifying tank, stirring until homogenized before discharging to obtain the face cream.

[0053] Example 5: Anti-wrinkle efficacy test of the polypeptide of the present invention

[0054] 5.1 Inclusion and Exclusion Criteria for Subjects

[0055] 5.1.1 Selection Criteria

[0056] (1) Healthy Chinese women aged 20-55;

[0057] (2) Dry, loose skin, redness, and a weak skin barrier (TEWL≥15g / h / m) 2 Those with forehead wrinkles, frown lines, crow's feet, nasolabial folds (wrinkle grade >2, refer to "Skin Aging Atlas"), or sensitive skin (lactic acid stinging ≥3 points);

[0058] (3) Physically healthy, with no other chronic diseases or diseases currently being treated;

[0059] (4) Voluntarily participate in the evaluation and sign an informed consent form;

[0060] (5) Willing to comply with all evaluation requirements.

[0061] 5.1.2 Exclusion Criteria

[0062] (1) Those who have used antihistamines in the past week or immunosuppressants in the past month;

[0063] (2) Those who have used any anti-inflammatory drugs on the test site within the past two months;

[0064] (3) Subjects with clinically unhealed inflammatory skin diseases;

[0065] (4) Patients with insulin-dependent diabetes mellitus;

[0066] (5) Patients with asthma or other chronic respiratory diseases who are currently receiving treatment;

[0067] (6) Those who have received anti-cancer chemotherapy within the past 6 months;

[0068] (7) Patients with immunodeficiency or autoimmune diseases;

[0069] (8) Breastfeeding or pregnant women;

[0070] (9) Patients who have undergone bilateral mastectomy and bilateral axillary lymph node dissection;

[0071] (10) Researchers participating in other clinical trials;

[0072] (11) Individuals with highly sensitive constitutions;

[0073] (12) Those with a history of skin diseases such as psoriasis, eczema, atopic dermatitis, or severe acne; or those with other chronic systemic diseases;

[0074] (13) Non-volunteer participants or those who cannot complete the prescribed content according to the test requirements.

[0075] 5.1.3 Precautions for Subjects

[0076] (1) Use the issued samples as required during the testing period;

[0077] (2) During the testing period, ensure that other lifestyle and dietary habits are not changed.

[0078] 5.1.4 Criteria for Quitting Midway

[0079] (1) Not selected (e.g., not meeting the selection criteria / or excluded by the exclusion criteria, etc.);

[0080] (2) Subjects were determined to be ineligible after being selected (including but not limited to changes in other lifestyle, diet, skin care habits and skin care samples during the evaluation period);

[0081] (3) The subject chose to withdraw;

[0082] (4) An adverse event or a serious adverse event occurs;

[0083] (5) Loss to follow-up;

[0084] (6) Force majeure;

[0085] (7) Others.

[0086] 5.2 Test Methods

[0087] 5.2.1 Method of using the product of this invention:

[0088] The polypeptide essence prepared using Example 2 of this invention is applied in 1 mL to the entire face each time, and massaged for 2-3 minutes to aid absorption, twice a day.

[0089] 5.2.2 Test Procedure

[0090] 5.2.2.1 Subjects' pre-use visit (D0) of the product of this invention

[0091] (1) Subject information registration, understanding and signing of informed consent form, and screening of subjects by laboratory technicians according to inclusion and exclusion criteria;

[0092] (2) Subjects cleaned their faces with the designated facial cleanser sample and sat quietly for 30 minutes in a laboratory with a temperature of 21±1℃ and a humidity of 50±10%RH.

[0093] (3) Testing the baseline skin values ​​of the subjects: PRIMOS-CR image capture;

[0094] (4) Laboratory technicians shall guide subjects on how to use the sample according to the sample usage requirements and the site of use, and provide written test precautions and instructions for use;

[0095] (5) The subject receives the sample and leaves the laboratory.

[0096] 5.2.2.2 Subjects using the product of this invention for 14 days (D14)

[0097] (1) Subjects cleaned their faces with the designated facial cleanser sample and sat quietly for 30 minutes in a laboratory with a temperature of 21±1℃ and a humidity of 50±10%RH.

[0098] (2) Skin data values ​​of test subjects 14 days after using the sample: PRIMOS-CR images;

[0099] 5.2.2.3 Subjects used the product of this invention for 28 days (D28).

[0100] (1) Subjects cleaned their faces with the designated facial cleanser sample and sat quietly for 30 minutes in a laboratory with a temperature of 21±1℃ and a humidity of 50±10%RH.

[0101] (2) Skin data values ​​of test subjects 28 days after using the sample: PRIMOS-CR images;

[0102] 5.2.3 Test Items

[0103] 5.2.3.1 The length and depth of forehead wrinkles, the area and depth of frown lines, the number and depth of crow's feet wrinkles, and the volume and depth of nasolabial folds.

[0104] The PRIMOS-CR instrument was used to test forehead wrinkles, frown lines, crow's feet, and nasolabial folds at D0, D14, and D28 respectively. The smaller the test value, the fewer the number of wrinkles; the smaller the wrinkle area; the smaller the wrinkle volume; the shorter the wrinkle length; and the shallower the wrinkle depth.

[0105] 5.2.3.2 Sensitive Skin Screening

[0106] On day D0, 50 μL each of 5% lactic acid aqueous solution and control group-distilled water were dropped onto a 0.8 cm diameter medical filter and applied to the nasolabial folds.

[0107] 5.2.4 Data Statistics

[0108] 5.2.4.1 Descriptive Statistics

[0109] Instrumental measurements: mean, standard deviation, maximum, minimum; Subject self-identity assessment: percentage of subjects who agree with the assessment.

[0110] 5.2.4.2 Difference Analysis

[0111] Statistical analysis software was used to perform statistical analysis on the data. All statistical analyses were two-tailed tests with a significance level of α = 0.05. Instrument measurements: conforming to a normal distribution, paired t-tests were used for comparisons before and after the same data; otherwise, the rank-sum test of two related samples was used.

[0112] 5.2.5 Criteria for Result Judgment

[0113] (1) Anti-wrinkle effect: Compared with before use, if any wrinkle parameter at any follow-up point is significantly improved after using the sample (P<0.05), the sample is judged to have anti-wrinkle effect; otherwise, the sample is judged not to have anti-wrinkle effect.

[0114] (2) Suitable for sensitive skin: After 28 days of use, no adverse skin reactions related to the sample were observed in any of the subjects with sensitive skin, and the sample was determined to be suitable for sensitive skin.

[0115] (3) Mild and non-irritating: After 28 days of use, no adverse skin reactions related to the sample were observed in any of the subjects, and 100% of the subjects agreed that the sample was mild and non-irritating, thus the sample was deemed mild and non-irritating.

[0116] 5.2.6 Test Results

[0117] 5.2.6.1 Subject Completion Status

[0118] This study included 33 female participants, with 32 ultimately completing the study. The participants ranged in age from 34 to 55 years, with a mean age of 48.22 ± 5.60 years.

[0119] 5.2.6.2 Feedback on adverse reactions during use

[0120] See Table 1 and Table 2.

[0121] Table 1 Results of human trial

[0122]

[0123] Table 2. Grading Standards for Adverse Skin Reactions

[0124] Classification Skin reaction 0 No response 1 faint erythema 2 Erythema, infiltration, papules 3 Erythema, edema, papules, vesicles 4 Erythema, edema, bullae

[0125] Note: This information is based on the grading standards for adverse skin reactions during human trials as specified in the 2015 edition of the "Cosmetic Safety Technical Specifications".

[0126] After using the product of this invention for 7 days, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred; after using it for 14 days, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred; after using it for 21 days, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred; after using it for 28 days, the skin reaction in the observation area was grade 0, and no adverse skin reaction occurred.

[0127] 5.2.6.3 Forehead wrinkle length

[0128] See Tables 3 and 4. Figure 1 .

[0129] Table 3 Results of forehead wrinkle length test

[0130]

[0131] Note: The smaller the value, the shorter the wrinkle length; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0132] Table 4 Statistical Analysis of Forehead Wrinkle Length Test Results

[0133]

[0134] Compared with before use, after using the product of this invention for 14 days, the length of forehead wrinkles decreased by 9.95%, which was significant; compared with before use, after using the product of this invention for 28 days, the length of forehead wrinkles decreased by 19.33%, which was also significant.

[0135] 5.2.6.4 Depth of forehead wrinkles

[0136] See Tables 5 and 6. Figure 2 .

[0137] Table 5 Results of the forehead wrinkle depth test

[0138]

[0139] Note: The smaller the value, the shallower the wrinkle depth; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0140] Statistical analysis of the results of the forehead wrinkle depth test in Table 6

[0141]

[0142] Compared with before use, after 14 days of using the product, the reduction rate of the forehead wrinkle depth was 11.80%, with a significant difference; Compared with before use, after 28 days of using the product, the reduction rate of the forehead wrinkle depth was 22.07%, with a significant difference.

[0143] 5.2.6.5 Area of the frown lines

[0144] See Table 7, Table 8 and Figure 3 .

[0145] Table 7 Results of the frown line area test

[0146]

[0147] Note: The smaller the value, the smaller the wrinkle area; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0148] Statistical analysis of the results of the frown line area test in Table 8

[0149]

[0150] Compared with before use, after 14 days of using the product, the reduction rate of the frown line area was 12.37%, with a significant difference; Compared with before use, after 28 days of using the product, the reduction rate of the frown line area was 20.68%, with a significant difference.

[0151] 5.2.6.6 Frown line depth

[0152] See Table 9, Table 10 and Figure 4 .

[0153] Table 9 Results of the frown line depth test

[0154]

[0155] Note: The smaller the value, the shallower the wrinkle depth; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0156] Statistical Analysis of the Test Results of the Depth of the Glabellar Lines in Table 10

[0157]

[0158] Compared with before use, after 14 days of using the product, the reduction rate of the depth of the glabellar lines was 10.40%, and the difference was significant; compared with before use, after 28 days of using the product, the reduction rate of the depth of the glabellar lines was 22.55%, and the difference was significant.

[0159] 5.2.6.7 Number of Crow's Feet

[0160] See Table 11, Table 12 and Figure 5 .

[0161] Test Results of the Number of Crow's Feet in Table 11

[0162]

[0163] Note: The smaller the value, the less the number of wrinkles is reduced; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0164] Statistical Analysis of the Test Results of the Number of Crow's Feet in Table 12

[0165]

[0166] Compared with before use, after 14 days of using the product, the reduction rate of the number of crow's feet was 11.92%, and the difference was significant; compared with before use, after 28 days of using the product, the reduction rate of the number of crow's feet was 23.17%, and the difference was significant.

[0167] 5.2.6.8 Depth of Crow's Feet

[0168] See Table 13, Table 14 and Figure 6 .

[0169] Test Results of the Depth of Crow's Feet in Table 13

[0170]

[0171] Note: The smaller the value, the shallower the wrinkle depth; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0172] Statistical Analysis of the Test Results of the Depth of Crow's Feet in Table 14

[0173]

[0174]

[0175] Compared with before use, after 14 days of product use, the depth of crow's feet wrinkles decreased by 8.88%, which was statistically significant; compared with before use, after 28 days of product use, the depth of crow's feet wrinkles decreased by 18.19%, which was statistically significant.

[0176] 5.2.6.9 Nasolabial fold volume

[0177] See Tables 15 and 16. Figure 7 .

[0178] Table 15 Results of Nasolabial Fold Volume Test

[0179]

[0180] Note: The smaller the value, the smaller the wrinkle volume; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0181] Table 16 Statistical Analysis of Nasolabial Fold Volume Test Results

[0182]

[0183] Compared with before use, after 14 days of product use, the volume of nasolabial folds decreased by 26.86%, which was statistically significant; after 28 days of product use, the volume of nasolabial folds decreased by 51.35%, which was statistically significant.

[0184] 5.2.6.10 Nasolabial fold depth

[0185] See Tables 17 and 18. Figure 8 .

[0186] Table 17 Results of Nasolabial Fold Depth Test

[0187]

[0188] Note: The smaller the value, the shallower the wrinkle depth; Reduction rate (%) = (Test value before use - Test value after use) / Test value before use * 100%

[0189] Table 18 Statistical Analysis of Nasolabial Fold Depth Test Results

[0190]

[0191] Compared with before use, after 14 days of product use, the nasolabial fold depth decreased by 9.19%, which was statistically significant; after 28 days of product use, the nasolabial fold depth decreased by 17.21%, which was statistically significant.

[0192] 5.2.6.11 Valid Examples

[0193] Effective examples of improving nasolabial folds Figures 9-11 .

[0194] Effective examples of improving frown lines are shown below. Figures 12-14 .

[0195] Effective examples of improving crow's feet wrinkles are shown below. Figures 15-17 .

[0196] Effective examples of improving forehead wrinkles Figures 18-20 .

[0197] 5.2.6.12 Security Assessment

[0198] Thirty-two subjects with sensitive skin (lactic acid stinging score ≥3) used the product of this invention for 28 days, and no adverse skin reactions occurred. The screening method for sensitive skin is shown in Tables 19 and 20.

[0199] Table 19 Subjective Evaluation

[0200]

[0201] Those with a total subjective evaluation score of ≥4 points will be screened for lactic acid stinging test.

[0202] Take 50 μL of 5% lactic acid solution and drop it onto a 0.8 cm filter. Apply this filter to the nasolabial fold on one side of the subject, with distilled water as a control on the other side. Ask the subject about their stinging sensation (stinging, itching, burning, or other) at 2.5 min and 5 min, and score them according to the "4-point method" in Table 20. Those whose cumulative stinging sensation on the lactic acid side relative to the distilled water side at 2.5 min and 5 min is >3 points are considered to have lactic acid stinging and can be judged as having sensitive skin.

[0203] Table 20 Lactic acid stinging rating scale

[0204] Rating levels Adverse reactions 0 No stinging sensation 1 Slight stinging 2 The stinging pain from the poisoning is tolerable. 3 The stinging pain from the poisoning is unbearable.

[0205] In summary, the peptides of this invention can significantly reduce the length and depth of forehead wrinkles, significantly reduce the area and depth of frown lines, significantly reduce the number and depth of crow's feet, and significantly reduce the volume and depth of nasolabial folds, demonstrating that the peptides of this invention have significant anti-wrinkle effects. The peptide essence of this invention is gentle and non-irritating, and no adverse reactions related to the peptides of this invention have been observed in subjects with sensitive skin.

Claims

1. Use of a polypeptide in the preparation of anti-aging skin care products; the amino acid sequence of the polypeptide is as shown in SEQ ID NO:

1.

2. The application according to claim 1, characterized in that: The anti-aging effect is to reduce facial wrinkles.

3. The application according to claim 2, characterized in that: The facial wrinkles are forehead wrinkles.

4. The application according to claim 2, characterized in that: The facial wrinkles are glabellar lines.

5. The application according to claim 2, characterized in that: The facial wrinkles are crow's feet.

6. The application according to claim 2, characterized in that: The facial wrinkles are nasolabial folds.

7. The application according to claim 1, characterized in that: The skin care products include lotions, aqueous solutions, serums, masks, creams, gels, sprays, gels, and powder injections.

8. The application according to claim 1, characterized in that: The addition amount of the polypeptide in the skin care products is 0.001 to 1.0 wt%.

Images